LMAT Lemaitre Vascular Earnings and EPS analysis

?
Relative Growth: Rel. Growth: 96
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 41
Relative Profitability: Rel. Profitability: 91

EPS in 2026 (TTM): $2.76

Last Report Period Date: Mar 31, 2026

Currently, LMAT's 12-month EPS stands at $2.76, according to the most recent financial reports. During 2025, LMAT reported a per-share earnings of $2.55, which shows a rise compared to the EPS of $1.96 recorded in 2024. LMAT recorded an EPS of $0.69 for the quarterly period ending on Mar 31, 2026.

LMAT earnings history

Historical annual and quarterly earnings per share (EPS) data for Lemaitre Vascular
EPS (TTM)
$2.76
EPS Growth YoY (Quarterly)
40.8%
EPS (Quarterly)
$0.69
EPS Growth (Quarterly)
0%

In 2025, Lemaitre Vascular's earnings per share was $2.55, a rise of 30.1% from $1.96 in 2024. Over the quarter ending Mar 31, 2026, the earnings per share came in at $0.69, reflecting a 40.8% increase compared to the same quarter a year earlier. As of March 2026, the TTM EPS is $2.76. During 2024, the annual earnings per share was $1.96, representing an increase of 44.1% compared to 2023.

LMAT earnings chart

LMAT EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
40.8%
EPS growth YoY
30.1%
EPS growth 3Y avg
39.5%
EPS growth 5Y avg
19.4%

Lemaitre Vascular has recorded a growth in earnings per share of 40.8% in the past 12 months (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 39.5% per year. Lemaitre Vascular had an average annual EPS growth of 19.4% in the last five years. When assessed over a ten-year period, LMAT's average EPS annual growth was 19.2%.

LMAT Earnings Waterfall

Breakdown of revenue, profit and net income for Lemaitre Vascular

LMAT Earnings vs Peers

What are the earnings of LMAT compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BSX Boston Scientific Corp 18.92 55.6% 63.3% N/A
LMAT Lemaitre Vascular Inc 33.32 30.1% 39.5% 19.4%
EW Edwards Lifesciences Corp 46.01 -73.6% -9.2% 6.9%
ANGO Angiodynamics Inc N/A 81.9% N/A N/A
BAX Baxter International Inc N/A -47.2% N/A N/A
TFX Teleflex Inc N/A -1,462.4% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.